| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 19, 2015First Implants Occur in Europe, Commencing Limited Market Release
Boston Scientific (NYSE: BSX) today announced that the first implants of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device – the latest generation of the WATCHMAN Device –...
-
Nov 9, 2015Topline data confirming peri-procedural safety of left atrial appendage (LAA) occlusion with the WATCHMAN™ Left Atrial Appendage (LAA) Closure device was presented in an oral session during the American Heart Association (AHA) Scientific Sessions.
This is the first study to collect real-world WATCHMAN LAA Closure Device experience outside of selected populations in randomized trials. Results from the prospective, multi-centre EWOLUTION...
-
Mar 13, 2015First-Of-Its-Kind Alternative to Long-Term Warfarin Therapy for Stroke Risk Reduction in Patients with Non-Valvular Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN Left Atrial Appendage Closure Device. The WATCHMAN Device offers a new...
-
Oct 9, 2014Comprehensive Clinical Data from Randomized Trials Reviewed
After reviewing updated data and analysis for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, the U.S. Food and Drug Administration (FDA)...
-
Dec 11, 2013
The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably by a majority, Yes: 13, No: 1, that the benefits of the...